These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 20107202

  • 21. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, Francis JL, Desaiah D, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Derby M.
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL, Zhang Y, Serra D, Wang Y, Ligueros-Saylan M, Dole WP.
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.
    Zhang X, Jordan P, Cristea L, Salgo M, Farha R, Kolis S, Lee LS.
    J Clin Pharmacol; 2012 Apr; 52(4):520-9. PubMed ID: 21558456
    [Abstract] [Full Text] [Related]

  • 30. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
    Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ, Miller J, Gutierrez MJ, Stoltz R, Gottesdiener KM, Herman GA, Wagner JA.
    J Clin Pharmacol; 2009 Aug; 49(8):937-46. PubMed ID: 19602719
    [Abstract] [Full Text] [Related]

  • 31. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M, Janssen K, Kakuda TN, Schöller-Gyüre M, Lachaert R, Hoetelmans RM, Woodfall B, De Smedt G.
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA, Sethuraman VS, Montague TH.
    Am J Cardiol; 2004 Jun 01; 93(11):1378-83, A6. PubMed ID: 15165918
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF.
    Int J Clin Pract; 2008 Dec 01; 62(12):1959-70. PubMed ID: 19166443
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W, Smulders R, Abeyratne A, Dietz A, Krauwinkel W, Kadokura T, Keirns J.
    Clin Ther; 2013 Aug 01; 35(8):1150-1161.e3. PubMed ID: 23910665
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Man versus machine: is there an optimal method for QT measurements in thorough QT studies?
    Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK.
    J Clin Pharmacol; 2006 Jun 01; 46(6):598-612. PubMed ID: 16707406
    [Abstract] [Full Text] [Related]

  • 39. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
    Lauring B, Dishy V, Luo WL, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, Lai E.
    J Clin Pharmacol; 2009 Dec 01; 49(12):1426-35. PubMed ID: 19833861
    [Abstract] [Full Text] [Related]

  • 40. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.
    Wang Z, Xuan F, Lin WH, Troyer MD, Tendolkar A, Cutler DL.
    Eur J Clin Pharmacol; 2013 Oct 01; 69(10):1761-7. PubMed ID: 23857248
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.